|
SPPH, BPAX, BSPM, MCLN, COTE, EMLL
Our Stocks to Watch tomorrow include Spencer Pharmaceutical Inc. (OTC: SPPH), BioSante Pharmaceuticals Inc. (OTC: BPAX), Biostar Pharmaceuticals Inc. (NASDAQ: BSPM), MedClean Technologies Inc. (OTCBB: MCLN), Coates International Ltd. (OTCBB: COTE) and El Maniel International Inc. (OTC: EMLL).
SPENCER PHARMACEUTICAL INCORPORATED (OTC: SPPH)
"Up 457.14% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/SPPH.php
Spencer Pharmaceutical Inc. develops drug platform technologies for the treatment of neurological deceases. The company specializes in the controlled release of existing therapeutic molecules in the areas of central nervous system, which include Alzheimer and Parkinson diseases, and brain cancer; and patented slow release drug delivery technology for the treatment of type-2 diabetes, arthritis, and other potential applications. It has operations primarily in North America and Europe. The company was incorporated in 1998 and is based in Boston, Massachusetts.
SPPH News:
No recent news for Spencer Pharmaceutical Inc. (OTC: SPPH).
BIOSANTE PHARMACEUTICALS INCORPORATED (NASDAQ: BPAX)
"Up 11.16% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/BPAX.php
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante's lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate technology (CaP) for novel vaccines, drug delivery and aesthetic medicine (BioLook™). Additional information is available online at www.biosantepharma.com.
BPAX News:
June 15 - Mergers and Acquisitions Activity Expected to Pick Up as a Result of Big Pharmaceuticals Expiring Patents
Five Star Equities Provides Stock Research on BioSante Pharmaceuticals and CytRx
Despite the recent economic turmoil in Europe, the Biotech Industry has been home to some of the strongest performers in the market in 2012. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 22 percent and 29 percent, respectively. As the world continues to face evolving health challenges the discoveries of new therapeutics and vaccines are critical. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on BioSante Pharmaceuticals Inc. (BPAX) and CytRx Corporation (CYTR).
Access to the full company reports can be found at:
www.FiveStarEquities.com/BPAX
www.FiveStarEquities.com/CYTR
Expiring patents have been a major dilemma for pharmaceutical companies. New products that are being introduced are not expected to generate the same level of revenues of the products that have lost patent protection. The Obama administration is currently analyzing a proposal in which the exclusivity period for biologics would be cut down by 5 years. Mergers & Acquisitions activity is expected to pick up in 2012 as companies look to make up for lost revenues. M&A allow companies to acquire products that are already proven in the market place without the hassle and costs associated with research and development.
"Many of the pharmaceutical companies started producing everything in-house out of their own R&D organizations and over time they've failed to produce enough that way. So the industry is now coalescing around a 50-50 model of half on your own and half bought in. There are some things we'll do for ourselves but we need to be constantly on the lookout for new technologies," said Angus Russell, Chief Executive of Shire PLC.
Five Star Equities releases regular market updates on companies in the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante is developing a portfolio of cancer vaccines, with 17 Phase I and Phase II clinical trials currently on-going. Four of these vaccines have been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA).
CytRx is a biopharmaceutical research and development company specializing in oncology. The CytRx oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. The company reported a net loss for the first quarter of 2012 of $10.1 million.
BIOSTAR PHARMACEUTICALS INCORPORATED (NASDAQ: BSPM)
"Up 2.95% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/BSPM.php
Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company's most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population.
BSPM News:
June 15 - Mergers and Acquisitions Activity Expected to Pick Up as a Result of Big Pharmaceuticals Expiring Patents
Five Star Equities Provides Stock Research on BioSante Pharmaceuticals and CytRx
Despite the recent economic turmoil in Europe, the Biotech Industry has been home to some of the strongest performers in the market in 2012. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 22 percent and 29 percent, respectively. As the world continues to face evolving health challenges the discoveries of new therapeutics and vaccines are critical. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on BioSante Pharmaceuticals Inc. (BPAX) and CytRx Corporation (CYTR).
Access to the full company reports can be found at:
www.FiveStarEquities.com/BPAX
www.FiveStarEquities.com/CYTR
Expiring patents have been a major dilemma for pharmaceutical companies. New products that are being introduced are not expected to generate the same level of revenues of the products that have lost patent protection. The Obama administration is currently analyzing a proposal in which the exclusivity period for biologics would be cut down by 5 years. Mergers & Acquisitions activity is expected to pick up in 2012 as companies look to make up for lost revenues. M&A allow companies to acquire products that are already proven in the market place without the hassle and costs associated with research and development.
"Many of the pharmaceutical companies started producing everything in-house out of their own R&D organizations and over time they've failed to produce enough that way. So the industry is now coalescing around a 50-50 model of half on your own and half bought in. There are some things we'll do for ourselves but we need to be constantly on the lookout for new technologies," said Angus Russell, Chief Executive of Shire PLC.
Five Star Equities releases regular market updates on companies in the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante is developing a portfolio of cancer vaccines, with 17 Phase I and Phase II clinical trials currently on-going. Four of these vaccines have been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA).
CytRx is a biopharmaceutical research and development company specializing in oncology. The CytRx oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. The company reported a net loss for the first quarter of 2012 of $10.1 million.
MEDCLEAN TECHNOLOGIES INCORPORATED (OTCBB: MCLN)
"Up 100.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/MCLN.php
MedClean Technologies, Inc. is a provider of innovative technology and services for the treatment and disposal of regulated medical waste. MedClean's flagship MedClean® Series systems are fully integrated, turnkey technology solutions that enable healthcare providers and medical waste haulers to safely, efficiently, and cost-effectively convert bio-hazardous regulated medical waste into sterile, unrecognizable material suitable for disposal as municipal solid waste. MedClean was founded in 1997 with corporate headquarters, research and development and distribution facilities now located in Bethlehem, Pennsylvania.
MCLN News:
May 15 - MedClean Technologies Announces 2011 Results
Company Increases 2011 Total Revenue 91% versus 2010
Company Schedules Shareholder Conference Call for May 21
MedClean Technologies, Inc. (OTCBB: MCLN) announced financial results for the 12-month period ended December 31, 2011.
2011 Year-end Operational Highlights
* Total revenue for 2011 increased 91% to $1,717,721 compared to $896,993 for 2010.
* Gross profit for 2011 increased 54% to $725,752 compared with gross profit of $470,295 for 2010.
* Net cash used in operating activities decreased to $1,1067,913 in 2011 from $1,882,435 in 2010.
2011 Fourth Quarter Operational Highlights
* Fourth quarter revenue, including system sales of $115,000 in the quarter, was $330,594.
* Maintenance Revenue of $59,423 held close to the quarterly projected amount of $62,000.
* Corrective Maintenance of $103,444 exceeded the quarterly projected amount of $74,000 and compares to $93,820 in the fourth quarter of 2010.
* MedClean's new ecommerce line of business (MedClean GPO), which was launched in the third quarter 2011, generated $42,205 for the full year 2011 and the acceleration initially expected during the first half of 2012 is now expected to start in the third quarter due to delays in launching new products. The Company continues to plan on introducing other mainstream consumable products such as red bags, autoclave bags boxes during 2012
* Consumables for MedClean Systems (cart liners, deodorizer, supplies, etc.,) generated revenue of $28,963 in the fourth quarter, below the Company's targeted run rate of $34,500 per quarter. Fluctuations are expected to occur quarterly in the future based upon customer needs.
"Year-over-year revenue results were extremely positive and we managed to continue to reduce our operational expenses while growing our revenue," stated David Laky, President & CEO of MedClean Technologies, Inc. "Our overall business plan has been well received by partners and peers in the market. The Company will continue to focus on building operational integrity through improving recurring revenue streams, implementing the localized processing center model, and managing operating expenses. We have also begun the process of investigating new business opportunities through tighter integration with partners and providers of industry related products and services that would benefit from our industry expertise and connectivity developed via our distributor and IMWTA hauler network. While I commend our team for the hard work and strong improvements in 2011, we all understand that we have to compound these improvements to scale our business model with the first goal of profitability while also expanding our addressable market with the new opportunities outside of one-time system sales."
Mr. Laky added, "We will be hosting a conference call with investors on Monday, May 21, 2012 at 1:30 p.m. The call will include an overview of our 2011 financial results and will include a question and answer session for shareholders. We feel this type of communication will provide the best forum to provide additional information on recent developments."
Full Year Financial Results
Total revenue for 2011 was $1,717,721 compared with $896,993 for 2010, representing a revenue increase of $820,729 or 91%. The net gain in revenue was attributed to an increase in MedClean System sales of $1,010,200, and a decrease of $(189,472) in the sale of consumables, component parts, and service contracts.
Revenues from MedClean System Sales for 2011 were $1,010,200 compared to $-0- in 2010.
Revenues derived from the sale of consumables, component parts and service contracts decreased to $707,521 compared to $896,993 in the prior year. The revenue was attributable to orders for goods and services from the Company's existing installed base of hospitals that have previously purchased a MedClean System. Service revenues decline in direct proportion to a reduction in corrective maintenance services work. Service billings will continue to fluctuate period to period based upon equipment service requirements.
The gross profit for 2011 was $725,752 (42.3% of total revenue) compared with a gross profit in 2010 of $470,295 (52.5% of total revenue). The decrease in gross profit margin as compared to the prior year can be attributed to lower profit margins on system sales. The components of costs of revenues for system sales include direct materials, depreciation, shipping and rigging costs, and contract labor.
Total operating expenses for 2011 were $3,579,315 compared with $4,787,192 for 2010, a decrease of $1,207,877 or 25.3%. In 2011, the Company incurred a $1,204,799 non-cash charge to operations for the fair value of vesting options and warrants as compared to $2,060,985 in 2010 and $0 in 2011 for stock based compensation as compared to $227,640 in 2010; a net decrease of $1,083,826, while other operating costs were reduced by $124,051 in 2011 versus 2010.
Net loss for 2011 was $(4,376,105) compared to a net loss in 2010 of $(4,417,550).
COATES INTERNATIONAL LIMITED (OTCBB: COTE)
"Up 16.67% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/COTE.php
Coates has been developing over a period of more than 15 years a patented spherical rotary valve CSRV Internal Combustion Engine invented by George J. Coates and his son Gregory. The CSRV system is adaptable to combustion engines of many types. This technology is currently adapted to a number of practical applications, including industrial generators powered by engines incorporating the CSRV technology and designed to operate on flare-off gas from oil wells, landfill gas and raw natural gas. The Company is actively engaged in preparing for the commencement of manufacturing of products utilizing this technology.
COTE News:
June 14 - Coates International, Ltd. Receives Updated Incentive Package From The Oklahoma Department Of Commerce
Coates International, Ltd. (OTCBB: COTE) (the "Company") has been advised that the State of Oklahoma has changed its incentive program and accordingly, has revised the package of incentives it is prepared to make available as an inducement to establish manufacturing operations within Oklahoma. Although the Company received this update today, it is dated October 25, 2011. The revised program is a ten-year incentive package from the Department of Commerce which provides us with the option to qualify for the Quality Jobs Cash Incentive package which could amount to $43,040,015 or the Investment/New Jobs Tax Credit package which could amount to $63,460,015. These incentives are earned based on the number of employees hired and the amount of investment in capital expenditures, inventory and cost of goods sold within Oklahoma. The scope of the Coates Oklahoma Engine Manufacturing, Ltd. ("Coates Oklahoma") operations established in Oklahoma will be scaled down to be consistent with the revised incentive package.
The Company has sublicenses in place which provide for license fees that are due currently of $5.8 million and additional license fees of $49 million. These sublicenses will begin to generate revenues and the Company will begin to receive the license fees after the CSRV natural gas CNG-LNG industrial engine generators are operating in the field and are being produced and delivered in sufficient quantities.
The Company has available to it a $20,000,000 USD Equity Line of Credit with Dutchess Opportunity Fund II, LP ("Dutchess") with a remaining unused portion of $19,700,000. This line enables to Company to receive net proceeds from sales of its common stock by Dutchess. The Company has also received an irrevocable Letter of Credit for $30,000,000 which must be accepted by a Commercial Bank as collateral for a loan to the Company before the funds can be utilized.
Coates Oklahoma Engine Manufacturing, Ltd. has estimated that the potential number new jobs created in Oklahoma to be approximately 300 in the first year growing to approximately 800 in the third year.
Management is presently reviewing its Coates Oklahoma business plans and intends to consider smaller sights for its manufacturing and production operations.
EL MANIEL INTERNATIONAL INCORPORATED (OTC: EMLL)
"Up 100.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/EMLL.php
El Maniel International Inc is a publicly traded company currently focusing in the gold business domain including but not limited to trading, prospecting, developing and expanding the economic potential of its world class mining claims and the company is committed in creating shareholder's value by ensuring constant development of current and new resources in its global gold business domain.
EMLL News:
No recent news for El Maniel International Inc. (OTC: EMLL).
|
